Clinical Trials Directory

Trials / Completed

CompletedNCT01881633

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
ISU Abxis Co., Ltd. · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single dosing study with three ascending dose cohorts of ISU302 in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGISU302
DRUGPlacebo

Timeline

Start date
2010-10-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2013-06-19
Last updated
2013-06-19

Source: ClinicalTrials.gov record NCT01881633. Inclusion in this directory is not an endorsement.